WallStreetZenWallStreetZen

NASDAQ: SMMT
Summit Therapeutics Inc Stock Ownership - Who owns Summit Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Summit Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Robert W. DugganCo-Chief Executive Officer2025-04-083,985,055$1.58
$6.30MBuy
Mahkam ZanganehCo-Chief Executive Officer2025-04-083,985,055$1.58
$6.30MBuy
Mahkam ZanganehCo-Chief Executive Officer2024-10-03315,681$1.58
$498.78kBuy
Bhaskar AnandChief Accounting Officer2024-09-1122,026$22.70
$499.99kBuy
Mahkam ZanganehCo-Chief Executive Officer2024-09-1144,052$22.70
$999.98kBuy
Manmeet Singh SoniCOO and CFO2024-09-1144,052$22.70
$999.98kBuy
Robert W. DugganCo-Chief Executive Officer2024-09-113,325,991$22.70
$75.50MBuy
Jeff HuberDirector2024-09-1144,052$22.70
$999.98kBuy

1 of 1

SMMT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SMMT insiders and whales buy or sell their stock.

SMMT Shareholders

What type of owners hold Summit Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Mahkam Zanganeh84.27%625,876,486$15.40BInsider
Robert W. Duggan79.63%591,418,593$14.55BInsider
Baker Bros Advisors LP3.29%24,424,865$601.10MInstitution
Yu Xia2.90%21,523,530$529.69MInsider
Maky Zanganeh2.01%14,915,775$367.08MInsider
Vanguard Group Inc1.57%11,670,576$287.21MInstitution
Blackrock Inc1.14%8,431,524$207.50MInstitution
Fmr LLC1.08%8,055,370$198.24MInstitution
Price T Rowe Associates Inc0.88%6,557,927$161.39MInstitution
State Street Corp0.75%5,602,910$137.89MInstitution

1 of 3

SMMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SMMT6.85%93.15%Net BuyingNet Buying
RPRX56.87%17.75%Net BuyingNet Buying
UTHR90.81%9.19%Net SellingNet Buying
GMAB91.82%0.00%
EXEL91.66%5.33%Net SellingNet Selling
View Top Biotech Stocks

Summit Therapeutics Stock Ownership FAQ

Who owns Summit Therapeutics?

Summit Therapeutics (NASDAQ: SMMT) is owned by 12.46% institutional shareholders, 169.30% Summit Therapeutics insiders, and 0.00% retail investors. Mahkam Zanganeh is the largest individual Summit Therapeutics shareholder, owning 625.88M shares representing 84.27% of the company. Mahkam Zanganeh's Summit Therapeutics shares are currently valued at $14.24B.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.